Biocept Inc (NASDAQ:BIOC) was up 5.6% during mid-day trading on Monday . The company traded as high as $0.80 and last traded at $0.75. Approximately 813,663 shares traded hands during trading, a decline of 38% from the average daily volume of 1,315,769 shares. The stock had previously closed at $0.71.

A number of equities research analysts have issued reports on BIOC shares. Zacks Investment Research downgraded Biocept from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. ValuEngine downgraded Biocept from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Chardan Capital restated a “buy” rating and set a $1.50 price target (down from $2.50) on shares of Biocept in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $2.25.

The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.27 and a current ratio of 1.41.

A hedge fund recently raised its stake in Biocept stock. Vanguard Group Inc. lifted its stake in shares of Biocept Inc (NASDAQ:BIOC) by 9.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 764,351 shares of the medical research company’s stock after acquiring an additional 66,746 shares during the quarter. Vanguard Group Inc. owned approximately 2.87% of Biocept worth $1,048,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.82% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Biocept (BIOC) Trading Up 5.6%” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.